Retinitis Pigmentosa

Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome

Nacuity Pharmaceuticals, Inc.

September 11, 2025